Jon Ellis and Simon Vanstone, PhD, go behind the headlines to explore the latest M&A activity and what tariffs and funding changes could mean for mRNA and beyond.

Eli Lilly (NYSE: LLY) has been one of the top-performing healthcare megacap stocks of the past decade. Eli Lilly is ...

BMO Capital Markets reiterated its Outperform rating on Eli Lilly and Company (NYSE:LLY), setting a price target of $900 ...

Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions ...

Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

Asad Haider, head of the healthcare business unit within Goldman Sachs Research, now forecasts the market for anti-obesity drugs, particularly those using injectable versions of GLP 1-based drugs, to ...

Detailed price information for Bank of Montreal (BMO-N) from The Globe and Mail including charting and trades.

Eli Lilly and Company and SiteOne Therapeutics, Inc., a private biotechnology company developing small molecule inhibitors of ...

About SiteOne Landscape Supply SiteOne supplies irrigation, lighting, landscape supplies, fertilizers, turf protection products, grass seed, turf care equipment and more. SiteOne Landscape Supply is ...

Pharmaceutical company Eli Lilly has announced plans to acquire private biotech company SiteOne in a deal worth up to $1 ...